Compare GFL Environmental Inc. Subordinate voting shares no par value (GFL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GFL Environmental Inc. Subordinate voting shares no par value vs Travere Therapeutics Inc. Common Stock — how do they compare? GFL Environmental Inc. Subordinate voting shares no par value trades at $43.48 (market cap $18.74B), while Travere Therapeutics Inc. Common Stock trades at $55.22 (market cap $5.02B). The key difference: GFL Environmental Inc. Subordinate voting shares no par value is far larger — about 3.7× Travere Therapeutics Inc. Common Stock's market cap, and GFL Environmental Inc. Subordinate voting shares no par value pays a 0.16% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GFL Environmental Inc. Subordinate voting shares no par value for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GFL | TVTX | |
|---|---|---|
Market Cap | $18.74B | $5.02B |
Volume | 3,882,806 | 2,060,842 |
Sector | Industrials | Health |
52-Week High | $46.51 | $67.52 |
52-Week Low | $33.54 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $25.73B | $5.15B |
Dividend Yield | 0.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GFL trades at $42.75, up 0.87% today, with a bullish technical signal from moving averages. Recent Q2 2026 earnings missed estimates, but the company raised full-year 2026 guidance. Revenue is projected to grow to $7.0B in 2026, though net income is expected to turn negative. The company recently acquired SECURE Waste Infrastructure and announced a quarterly dividend, signaling financial activity.
Outlook is mixed: strong analyst buy consensus (77.8%) and positive news flow support upside, but negative profit margins and high valuation ratios pose risks. The stock's performance hinges on execution of growth initiatives and margin improvement in a competitive industrial sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.
Read more on GFL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
